Abbott Laboratories (ABT)

Abbott Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	-	8,522	7,616	6,896	9,882	9,799
Short-Term Investments	-	417	351	383	288	450
Trading Asset Securities	-	-	1	-	-	-
Cash & Short-Term Investments	5,603	8,939	7,968	7,279	10,170	10,249
Cash Growth	-27.54%	12.19%	9.47%	-28.43%	-0.77%	43.38%
Receivables	-	7,929	6,925	6,565	6,218	6,487
Inventory	-	6,488	6,194	6,570	6,173	5,157
Prepaid Expenses	-	2,532	2,179	2,087	2,251	2,054
Other Current Assets	-	108	390	169	412	292
Total Current Assets	-	25,996	23,656	22,670	25,224	24,239
Property, Plant & Equipment	-	12,942	11,733	11,276	10,278	10,112
Long-Term Investments	-	595	573	485	468	512
Goodwill	-	24,035	23,108	23,679	22,799	23,231
Other Intangible Assets	-	5,526	6,647	8,815	10,454	12,739
Long-Term Deferred Tax Assets	-	-	-	5,975	-	-
Other Long-Term Assets	-	17,619	15,697	314	5,215	4,363
Total Assets	-	86,713	81,414	73,214	74,438	75,196

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	-	4,240	4,195	4,295	4,607	4,408
Accrued Expenses	-	7,173	6,200	6,543	6,925	6,464
Current Portion of Long-Term Debt	-	3,033	1,500	1,080	2,271	754
Current Portion of Leases	-	276	254	245	230	245
Current Income Taxes Payable	-	569	594	492	343	306
Other Current Liabilities	-	1,205	1,414	1,186	1,113	928
Total Current Liabilities	-	16,496	14,157	13,841	15,489	13,105
Long-Term Debt	-	9,896	12,676	13,694	14,522	17,296
Long-Term Leases	-	931	896	949	943	956
Pension & Post-Retirement Benefits	-	2,125	1,880	1,964	1,784	2,738
Long-Term Deferred Tax Liabilities	-	559	512	568	991	1,392
Other Long-Term Liabilities	-	3,935	3,392	3,371	3,804	3,685
Total Liabilities	-	33,942	33,513	34,387	37,533	39,172

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	-	25,527	25,153	24,869	24,709	24,470
Retained Earnings	-	49,781	47,261	37,554	35,257	31,528
Treasury Stock	-	-17,177	-16,844	-15,981	-15,229	-11,822
Comprehensive Income & Other	-	-6,001	-7,906	-7,839	-8,051	-8,374
Total Common Equity	51,110	52,130	47,664	38,603	36,686	35,802
Minority Interest	-	641	237	224	219	222
Shareholders' Equity	51,762	52,771	47,901	38,827	36,905	36,024
Total Liabilities & Equity	-	86,713	81,414	73,214	74,438	75,196

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	32,720	14,136	15,326	15,968	17,966	19,251
Net Cash (Debt)	-27,117	-5,197	-7,358	-8,689	-7,796	-9,002
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-15.55	-2.97	-4.21	-4.97	-4.42	-5.03
Filing Date Shares Outstanding	1,738	1,738	1,734	1,735	1,738	1,763
Total Common Shares Outstanding	1,738	1,737	1,732	1,734	1,738	1,764
Working Capital	-	9,500	9,499	8,829	9,735	11,134
Book Value Per Share	29.54	30.02	27.52	22.26	21.11	20.29
Tangible Book Value	-1,345	22,569	17,909	6,109	3,433	-168
Tangible Book Value Per Share	-0.78	13.00	10.34	3.52	1.98	-0.10
Land	-	541	528	529	511	525
Buildings	-	4,543	4,207	4,161	4,053	4,007
Machinery	-	17,571	15,517	15,179	14,164	13,528
Construction In Progress	-	2,567	2,488	2,064	1,484	1,304

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Oct 21, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error